European stocks slipped on Wednesday as geopolitical uncertainty lingered, and investors awaited talks between Donald Trump and Xi Jinping as the countries levy tariffs on one another.

The pharmaceutical giant is now targeting more than £40billion in annual revenue by 2031, compared to a previous outlook of ...

GSK shares surge as the drugmaker raises its 2031 sales target to over £40bn, boosts dividends, and announces a £2bn share buyback plan.

The pharma giant hiked its 2031 sales forecast to more than £40bn, up from £38bn, after reporting better than forecast fourth quarter earnings.

(Reuters) - European shares were flat in early trade on Wednesday, as gains led by healthcare stocks following drugmaker Novo ...

Pharmaceutical giant GlaxoSmithKline (GSK) has lifted its long-term sales guidance as it hailed a strong drug pipeline. It came as the boss of the London-listed firm cheered an “excellent” performance ...

GSK Plc announced a share buyback of £2 billion as it saw better than expected profit in the fourth quarter. The share ...

Tinea Pedis Treatment Industry Regional Analysis Tinea Pedis Treatment Market Journal of the American Academy of Dermatology foun ...

Shares of GSK plc (NYSE:GSK – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the nine research firms that are covering the stock, Marketbeat reports. Six ...

Sir Jonathan Van-Tam will work across the Health & Life Sciences client portfolio as it growsLONDON, Feb. 03, 2025 (GLOBE ...

Blue Trust Inc. lifted its position in GSK plc (NYSE:GSK – Free Report) by 16.7% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 12,505 shares of the pharmaceutical ...

ViiV Healthcare has secured European Commission approval for its long-acting HIV treatment, Vocabria + Rekambys, for adolescents aged 12 and olde ...